Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems-Trading Strong Earnings Growth and Momentum -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (5038)	2/21/2001 12:16:23 PM
From: Jenna	Read Replies (1) \| Respond to of 6445

CIMA Labs Announces FDA Approval of Zomig-ZMT (CIMA beckoned at 2:45 in the morning already, thanks for the nudge, CIMA) Antimigraine Product Based on CIMA's Fast-Dissolve DuraSolv(TM) Drug Delivery Technology EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Feb. 14, 2001-- CIMA Labs, Inc. (Nasdaq:CIMA - news) today announced that AstraZeneca (NYSE:AZN - news) has received U.S. marketing approval from the Food and Drug Administration (FDA) for Zomig-ZMT(TM) (zolmitriptan), an orally disintegrating antimigraine compound incorporating CIMA's DuraSolv fast-dissolve drug delivery system with AstraZeneca's active drug ingredient, zolmitriptan.